Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy

Files in this item

This item appears in the following Collection(s)

Search DSpace



Browse

My Account

Statistics